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Sciences-Oncology Center, and {Center of Cancer Nanotechnology Excellence, The Johns Hopkins University, Baltimore, MarylandABSTRACT CD44 is a multifunctional glycoprotein that binds to hyaluronan and fibrin(ogen). Alternative splicing is responsible
for the generation of numerous different isoforms, the smallest of which is CD44s. Insertion of variant exons into the extracellular
membrane proximal region generates the variant isoforms (CD44v). Here, we used force spectroscopy to delineate the biophys-
ical and molecular requirements of CD44-HA and CD44-fibrin(ogen) interactions at the single-molecule level. CD44v-HA and
CD44s-HA single bonds exhibit similar kinetic and micromechanical properties because the HA-binding motif on CD44 is
common to all of the isoforms. Although this is the primary binding site, O- and N-linked glycans and sulfation also contribute
to the tensile strength of the CD44-HA bond. The CD44s-fibrin pair has a lower unstressed dissociation rate and a higher tensile
strength than CD44s-fibrinogen but is weaker than the CD44-HA bond. In contrast to CD44-HA binding, the molecular interaction
between CD44 and fibrin(ogen) is predominantly mediated by the chondroitin sulfate and dermatan sulfate on CD44. Blocking
sulfation on CD44s modestly decreases the tensile strength of CD44s-fibrin(ogen) binding, which is in stark contrast to CD44v-
fibrin interaction. Collectively, the results obtained by force spectroscopy in conjunction with biochemical interventions enable us
to delineate the biophysical parameters and molecular constituents of CD44 binding to hyaluronan and fibrin(ogen).INTRODUCTIONCD44 is a multitasking protein that plays a pivotal role in
a number of physiological processes, including inflamma-
tion, hematopoiesis, wound healing, and cancer metastasis.
CD44 is a type I transmembrane glycoprotein encoded by
a single gene, and comprises at least 20 exons (1). Exons
1–5, 16–18, and 20 are spliced together to form the smallest
CD44 transcript, known as the standard CD44 isoform
(CD44s; Fig. 1 A). At least 10 exons (exons 6–15, typically
identified as v1–v10) can be alternatively spliced and in-
serted at a single site within the membrane-proximal portion
of the extracellular domain to give rise to multiple variant
isoforms of CD44 (Fig. 1 A). CD44 undergoes extensive
post-translational modifications resulting from the attach-
ment of carbohydrates to N- and O-linked glycosylation
sites of the extracellular domain, and of glycosaminogly-
cans (GAGs) such as chondroitin sulfate (CS), dermatan
sulfate (DS) (2), heparan sulfate (3), and keratan sulfate
(4) (Fig. 1 A).
CD44 is the major cell surface receptor for hyaluronan
(or hyaluronic acid (HA)), a nonsulfated glycosamino-
glycan (GAG) that is composed of repeating units of
D-glucuronic acid and N-acetyl-D-glucosamine (1). HA
is a major component of the extracellular matrix in most
mammalian tissues, and is upregulated on the surface of
endothelial cells upon proinflammatory stimuli (5,6).
CD44-HA binding has been implicated in the migration
of activated leukocytes and lymphocytes to sites of inflam-
mation, presumably by attachment to vascular endothelialSubmitted April 26, 2012, and accepted for publication June 18, 2012.
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0006-3495/12/08/0415/9 $2.00cell walls (7,8). CD44-HA interactions also play a key
role in matrix-dependent migration pertaining to inflamma-
tion and cancer metastasis. Although both the standard and
variant isoforms bind HA, some studies have suggested that
CD44s binds more efficiently than CD44v (9–11), whereas
others have shown the opposite (12). These conflicting data
may be attributed to subtle changes in the expression levels
of CD44s versus CD44v on the cell surface. To eliminate
the potential effects of differential expression of CD44s
versus CD44v on the efficiency of HA binding, we sought
to determine the kinetic and micromechanical properties of
the aforementioned pairs at the single-molecule level. To
that end, we used a micromanipulation method based on
single-molecule force spectroscopy to investigate these
biomolecular interactions at short and long dwell times,
thereby simulating the receptor-ligand encounter time at
high and low shear regimes, respectively (13–15). HA immo-
bilized on a cantilever tip was brought into contact for
prescribed durations of contact with immunopurified CD44
incorporated into lipid vesicles and layered onto a polye-
thyleneimine (PEI)-cushioned glass slide. CD44v-HA and
CD44s-HA bonds display a similar tensile strength, un-
stressed dissociation rate, and reactive compliance, which
is explained by the fact that the HA-bindingmotif is common
to all CD44 isoforms.Moreover,O- andN-linked glycans and
sulfation contribute to the tensile strength of CD44-HA
binding.
CD44 also interacts with fibrin and fibrinogen (16–18).
However, it remains to be determined how the different
molecular constituents influence the biophysical proper-
ties of these receptor-ligand bonds at the single-molecule
level. Using force spectroscopy, we determined that thehttp://dx.doi.org/10.1016/j.bpj.2012.06.039
FIGURE 1 Single-molecule force spectroscopy as used to probe the
biomechanical properties of CD44s-fibrin(ogen) bonds. (A) Schematic
diagram of the standard and variant isoforms of CD44. Orange hexagons
represent putative sites of N-linked glycosylation; green circles represent
putative sites for O-linked glycosylation (SS, disulfide bond; P, serine
phosphatases). (B) Schematic diagram of the MFP used to investigate the
kinetic and micromechanical properties of receptor-ligand interactions
at single-molecule resolution. (C) CD44s was immunoprecipitated from
HL60 human myeloid leukemia cells, and CD44v was immunoprecipitated
from LS174T colon carcinoma cells and subjected to SDS-PAGE under
reducing conditions, followed by Western blotting using the anti-CD44
mAb 2C5. (D) Typical force-distance traces acquired from force spectros-
copy experiments in which fibrin or fibrinogen immobilized on a cantilever
tip was brought into contact hundreds of times with immunopurified CD44s
incorporated into lipid vesicles and layered onto a PEI-cushioned glass
slide. The red arrows in the first two curves indicate two distinct CD44s-
fibrin rupture events. The rupture event in the red box is enlarged on the
right to show the drop in the force. The slope before rupture multiplied
by the retraction velocity gives the loading rate. The third curve is typically
obtained when there is no binding. The scale bar for the three curves is also
indicated.
416 Raman et al.CD44s-fibrin bond is mechanically stronger than the CD44s-
fibrinogen pair, but more labile than CD44-HA. The
CD44-fibrin(ogen) molecular recognition is predominantly
dependent on CS and DS GAGs on CD44. Of note, sulfation
exerts opposite effects on the biophysical properties of
CD44s-fibrin versus CD44v-fibrin bonds. Taken together,
our single-molecule characterization studies resolve the
differences documented in the literature pertaining to
CD44-HA interactions, and delineate the critical role of the
molecular constituents involved in CD44 binding to its
counter-receptors.MATERIALS AND METHODS
Reagents and monoclonal antibodies
Fibrinogen (von Willebrand factor, plasminogen, and fibronectin free) was
obtained from Enzyme Research Laboratories (South Bend, IN). Thrombin,
chondroitinase ABC (Proteus vulgaris), benzyl 2-acetamido-2-deoxy-a-D-Biophysical Journal 103(3) 415–423galactopyranoside (benzyl-GalNAc), HA, and sodium chlorate were ob-
tained from Sigma Chemical Company (St. Louis, MO). Sialidase (Vibrio
cholerae) was obtained from Roche Applied Science, and PNGaseF was
obtained from New England Biolabs (Ipswich, MA). Anti-human CD44
monoclonal antibody (mAb) 2C5 was obtained from R&D Systems (Min-
neapolis, MN). The anti-human CD44 mAb 515 was obtained from BD
Biosciences (San Jose, CA). PEI was obtained from Polysciences (Warring-
ton, PA), and 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) was
obtained from Avanti Polar Lipids (Alabaster, AL).Cell culture, whole-cell lysis, and
immunoprecipitation
LS174T human colon adenocarcinoma cells and HL60 human myeloid
cells were obtained from the American Type Culture Collection (Manassas,
VA) and cultured in the recommended medium. LS174T or HL60 whole-
cell lysate was prepared by membrane disruption using 2% Nonidet P-40
(Sigma Chemical) followed by differential centrifugation. CD44v was
immunoprecipitated from LS174T colon carcinoma cell lysate with the
anti-CD44 mAb 2C5. Of note, LS174T metastatic colon carcinoma cells
express predominantly the CD44 variants v3, v5, v7, and v8, whereas the
variant regions v4, v6, and v10 are present in a small percentage of isoforms
(19). CD44s was immunoprecipitated from HL60 human myeloid cell
lysates with anti-CD44 mAb 515 using recombinant protein G-agarose
beads (Invitrogen) (16,19,20).Lipid bilayer preparation
To prepare lipid solutions, we dissolved 8 mg of DMPC in 8 ml of lipid
buffer B (20 mM Tris-HCl, 50 mM NaCl, 1 mM CaCl2, 0.1% (w/v) Triton
X-100). To 400 ml of lipid solution, 100 ml of CD44s or CD44v at a concen-
tration of 100 mg/ml was added and incubated at 37C for 2 h (21). The
lipid-protein solution was transferred to a 10 kDa MWCO dialysis cassette
and dialyzed against 1L of lipid buffer A (20 mM Tris-HCl, 50 mM NaCl,
1 mM CaCl2) three times for 12 h each. Lipid-protein solutions were then
stored at 4C under argon for up to 1 month. To prepare bilayers, glass
slides were cleaned with plasma oxygen for 5 min and immediately sub-
merged in a solution of 100 ppm PEI in 0.5 mM KNO3 for 20 min before
they were rinsed with deionized water and dried with nitrogen. The slides
were further dried in a vacuum desiccator overnight before use. The PEI-
coated slides were then incubated with a 4 ml droplet of the lipid-protein
solution for 1–2 h under a slightly dampened towel to prevent complete
dehydration. The slides were then rinsed with Hank’s balanced salt solution
(HBSS) and flooded with HBSS for use in molecular force probe (MFP)
experiments. In select experiments, the DMPC-CD44s solution was pre-
mixed with 20 mg/ml Hermes-1 anti-CD44 mAb before incubation on the
glass slide (15).SDS-PAGE and Western blotting
Immunoprecipitated CD44v and CD44s were resolved on a 4–20% Tris-
HCl Criterion gel (Bio-Rad) using Tris/glycine running buffer under
reducing conditions. Resolved proteins were transferred to immunoblot
polyvinylidene diflouride membranes and stained with the anti-CD44
mAb 2C5 (Fig. 1 C) (16,20).Treatments with inhibitors and enzymes
To degrade all forms of CS and DS, we incubated CD44s-incorporated lipid
bilayers for 1 h at 37C with 1 U/ml P. vulgaris chondroitinase ABC before
obtaining force spectroscopy measurements (15,16). To cleave N-linked
glycans from CD44, immunopurified LS174T CD44v and HL60 CD44s
were treated with PNGase F for 1 h at 37C according to the manufacturer’s
CD44-HA and CD44-Fibrin(ogen) Binding 417specification (16,19). Before conducting metabolic inhibitor studies, we
pretreated the LS174T and HL60 cell suspensions (107 cells/ml) with
0.1 U/ml V. cholerae sialidase for 60 min at 37C to remove terminal sialic
acid residues and ensure de novo synthesis of newly generated HECA-452
reactive carbohydrate structures. Subsequently, LS174Tor HL60 cells were
cultured for 48 h at 37C in medium containing 2 mM benzyl-GalNAc
to inhibit O-linked glycosylation (16,19,20). To inhibit sulfation, CD44v
was immunopurified from LS174T colon carcinoma cells, which were
cultured for 48 h at 37C in medium containing 60 mM sodium chlorate,
and CD44s was immunopurified from HL60 human myeloid cells that
were cultured in medium containing 20 mM sodium chlorate (16). DPBS
was used as a diluent control.Cantilever functionalization
To obtain a surface that would readily bind soluble proteins, we silanized
MFP cantilevers (Bruker Nano, Camarillo, CA) with 2% 3-aminopropyl-
triethoxysilane (13–15,22). The cantilevers were then incubated in a
5 mg/ml solution of fibrinogen in DPBS containing 50-fold molar excess
of the cross-linker bis(sulfosuccinimidyl) suberate (BS3; Pierce, Rockford,
IL) for 30 min followed by quenching with Tris buffer. To form fibrin, the
cantilever tips were incubated with 2 U/ml thrombin in DPBS for 2 h at
37C, followed by immersion in Tris buffer to block nonspecific interac-
tions (15). In control experiments, the silanized cantilevers were incubated
with a 2 U/ml solution of thrombin in DPBS containing BS3 for 30 min
followed by quenching with Tris buffer. Carbodiimide chemistry using
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) and N-hydroxysulfosuc-
cinimide (both from Pierce, Rockford, IL) was employed to activate the
carboxylic groups on HA to form a covalent bond with the amine groups
of the silanized tips according to the manufacturer’s specifications (23).Single-molecule force spectroscopy, data
acquisition, and analysis
We conducted experiments using an MFP (Asylum Research, Santa Bar-
bara, CA) (13–15,22). We calibrated the softest triangular cantilever
(C type cantilever, MLCT probes) using the thermal noise amplitude and
measured its deflection by laser reflection onto a split photodetector
(Fig. 1 B). The distance between the cantilever and the DMPC-CD44
bilayer was adjusted so that each approach cycle resulted in a depression
force of ~1 nN before reproach (14). The reproach velocity was varied
from 5 mm/s to 25 mm/s, and the dwell time between the cantilever and
the bilayer was varied from 2 to 200 ms. We derived the rupture forces
and corresponding loading rates from force-distance traces using IgorPro
4.09 software (Wavemetrics, Lake Oswego, OR; Fig. 1D). For each consid-
ered receptor-ligand pair, rupture force measurements from>1000 success-
ful binding events were first rank-ordered by the magnitude of the loading
rate. Then, rupture forces from 50 rupture events of increasing magnitude
were ensemble-averaged for rates up to 100 pN/s, and from 100 rupture
events for rates > 100 pN/s (24,25). For each set of binned data, a mean
adhesion force and loading rate were calculated and used to fit Bell model
parameters. The Bell model parameters (the unstressed dissociation rate
koff and the reactive compliance xb) were tabulated by a least-squares fit
to the linear region of a graph of rupture force against the logarithm of
the loading rate (13–15).Preparation of CD44-coated microspheres
Before protein binding was performed, 10-mm polystyrene microspheres
(2.5  107 microspheres/ml; Bangs Labs, Fishers, IN) were washed three
times with DPBS, followed by two washes with citrate-phosphate buffer
(pH 3.0). After 1 h of incubation at room temperature (RT), the micro-
spheres were washed once more with the citrate-phosphate buffer, three
times with DPBS, and two times with binding buffer (0.2 M carbonate/bicarbonate buffer, pH 9.2). Immunoprecipitated CD44 from LS174T or
HL60 whole-cell lysate was diluted to the desired concentrations with
binding buffer and incubated with the microspheres overnight at 4C
with constant rotation. Microspheres were washed two times with DPBS
and subsequently blocked with DPBS, 1% BSA for 1 h at RT. Subsequently,
the microspheres were resuspended (2  106 microspheres/ml) in DPBS,
0.1% BSA for use in flow-based adhesion assays (16,20).Flow-based adhesion assays
We prepared HA-coated surfaces by incubating 50 mg/ml HAwith binding
buffer on untreated 35-mm polystyrene suspension culture dishes overnight
at 4C. The plates were then washed with DPBS and blocked with 1% BSA
for 1 h before they were used in flow-based adhesion assays. Suspensions of
microspheres (2  106/ml) were perfused over HA-coated dishes using
a parallel plate flow chamber (250 mm channel depth, 5.0 mm channel
width). The microspheres were allowed to adhere and roll. Average rolling
velocities were computed as the distance traveled by the centroid of the
translating microsphere divided by the time interval at the given wall shear
stress (19,20).Statistics
The statistical significance of differences between means was determined
by Student’s t-test. Values of p < 0.05 were considered to be statistically
significant.RESULTS AND DISCUSSION
Comparison of the kinetic and micromechanical
properties of CD44v-HA and CD44s-HA single
bonds
HA is the major ligand for CD44. The HA-binding motif in
the N-terminal domain of CD44, specifically amino acid
residues 32–123, is common to both the standard and variant
isoforms of CD44 (1). However, previous studies have
shown that CD44v and CD44s bind HA with different effi-
ciencies. Conflicting results indicate that CD44v binds HA
with greater efficiency than CD44s (12), and vice versa
(9–11). To eliminate the possibility that differential expres-
sion levels of CD44 dictated these conflicting data, we first
performed a macroscopic cell-free, flow-based adhesion
assay in which beads coated with an equivalent density of
LS174T CD44v or HL60 CD44s molecules were perfused
over immobilized HA substrates under flow. Both the
CD44v- and CD44s-decorated microspheres adhered and
exhibited similar rolling velocities on HA substrates at shear
stress levels of 0.25 and 0.5 dyn/cm2 (Fig. 2 A). The lack of
dependence of the rolling velocity on shear stress has also
been noted by other groups for shear stresses <1 dyn/cm2
(26,27).
We next wished to compare the binding of HA to
immunopurified LS174T CD44v relative to HL60 CD44s
(Fig. 1 C) at the single-molecule level using short and long
dwell times, thereby simulating the receptor-ligand encoun-
ter time at high (0.5 dyn/cm2) and low (0.005 dyn/cm2)
shear regimes, respectively. CD44v or CD44s was recon-
stituted in DMPC lipid vesicles and then layered ontoBiophysical Journal 103(3) 415–423
FIGURE 2 Kinetic and micromechanical properties of CD44-HA bind-
ing at the single-molecule level. (A) Average rolling velocities (mm/s) of
microspheres (2  106/ml) decorated with either CD44v immunopurified
from LS174T cells or CD44s immunopurified from HL60 cells on 50
mg/ml HA at prescribed wall shear stresses. Data represent the mean 5
SE from n ¼ 3 independent experiments. (B) Frequency of binding events
between HA and CD44v or CD44s in the absence and presence of the func-
tion-blocking CD44 antibody Hermes-1. DMPC-CD44v or DMPC-CD44s
lipid solutions were premixed with 20 mg/ml of the Hermes-1 mAb just
before bilayers were formed on PEI-coated glass slides. Data represent
the mean5 SE of n ¼ 3 independent experiments; *p < 0.05 with respect
to control. (C) Rupture force (pN) as a function of loading rate (pN/s) for
CD44v-HA and CD44s-HA interactions. Data were acquired for a range
of retraction velocities from 5 to 25 mm/s, using a dwell time of 20 ms.
Data represent the mean5 SE of n ¼ 4–6 experiments, with each experi-
ment having at least 1200 approach/reproach cycles.






CD44v-P-selectin (15) 0.165 0.03 0.365 0.01
CD44v-fibrin (15) 0.435 0.1 0.45 0.05
CD44s-fibrin 0.445 0.05 0.35 0.01
CD44s-fibrinogen 0.625 0.06 0.325 0.02
CD44v-HA 0.0055 0.003 0.595 0.12
CD44s-HA 0.0045 0.002 0.555 0.05
Bell model parameters were tabulated by a least-squares fit to the linear
region of the rupture force versus the logarithm of loading rate. Data are ex-
pressed as mean5 SD.
418 Raman et al.a PEI-cushioned glass slide (15). The hydrophobic interac-
tions between the lipid and the transmembrane domain of
CD44 allowed it to be incorporated into the bilayer in the
proper physiological orientation. In these experiments, we
employed an MFP (Fig. 1 B). This device uses a small, flex-
ible cantilever that deflects in response to forces generated
between the HA-coated cantilever tip and CD44v or CD44s
molecules incorporated into lipid bilayers when they are
repeatedly brought into contact for 20ms. As shown in repre-
sentative force-distance traces, receptor-ligand unbinding at
any given reproach velocity (5–25 mm/s) involved a single
force step rather thanmultiple ones (Fig. 1D). The prominent
first peak in the force-distance traces of Fig. 1 D is due
to nonspecific interactions occurring just after tip-substrate
contact (commonly referred to as jump-off-contact) but
before specific receptor-ligand unbinding (28). To further
ensure that most binding events were mediated by a single
receptor-ligand pair, we achieved a low probability (13) of
binding (15–30%) by decorating the cantilever and lipid
bilayers with dilute HA and CD44 concentrations, respec-
tively. The function-blocking anti-CD44 mAb Hermes-1Biophysical Journal 103(3) 415–423abrogated the binding from ~20% down to baseline levels,
suggesting that this is the primary binding site on CD44 for
HA (Fig. 2 B).
The average rupture force of CD44v-HA and CD44s-HA
bonds grew linearly with the natural log of the loading rate
(Fig. 2 C). Moreover, the mean bond rupture forces at all
loading rates were nearly identical for both receptor-ligand
pairs. The Bell model parameters (i.e., the unstressed disso-
ciation rate koff (s
1) and reactive compliance xb (nm))
were extracted from least-squares fits of the mean rupture
force versus the logarithm of loading rate for HA binding
to LS174T CD44v or HL60 CD44s (Fig. 2 C). The respec-
tive values for the off-rate and reactive compliance were also
similar for the LS174T CD44v-HA (0.005 5 0.003 s1,
0.59 5 0.12 nm) and HL60 CD44s-HA (0.004 5
0.002 s1, 0.555 0.05 nm) pairs. From the experimentally
calculated koff (s
1) and xb (nm), the Bell model based
dissociation rate koff was used to plot the bond lifetime
(1/koff) as a function of the applied force (see Fig. S1 in
the Supporting Material). At 80 pN, the bond lifetime drops
to 2 ms for the CD44v-HA pair, and to 5.4 ms for the
CD44s-HA pair. Of note, the shear stress of 0.25 dyn/cm2
corresponds to a hydrodynamic force of ~80 pN acting on
a 10-mm PSGL-1-coated microsphere tethered on a selectin
substrate (29,30). Taken together, the macroscopic flow-
based adhesion assay and single-molecule force spectros-
copy data reveal that CD44v and CD44s bind HA with
similar affinity. Our data are supported by findings that the
HA-binding site, which is common to CD44v and CD44s,
is the primary binding site on CD44 because Hermes-1
nearly abrogates these binding interactions (Fig. 2 B). It is
notable that the koff (s
1) of CD44-HA binding is lower
than that of CD44v-P-selectin (Table 1) (15). This helps
explain the more stable and slower CD44-mediated rolling
on HA compared with P-selectin substrates (31).Roles of O- and N-glycosylation and sulfation in
CD44-HA binding kinetics
Conflicting results regarding the effects of O-glycosylation
of CD44 on its binding to HA have been obtained, depend-
ing on the cell types used and the method of stimulation
CD44-HA and CD44-Fibrin(ogen) Binding 419used in cells that do not constitutively bind HA (32).
O-glycosylation has been shown to either positively or nega-
tively regulate CD44-HA binding, or to not even affect it, in
various cell lines (9,33–36). Force spectroscopy revealed
that inhibition of O-glycosylation did not cause any signif-
icant alteration in the frequency of binding of CD44v or
CD44s to HA at both of the contact durations tested, as
well as at 20 ms (data not shown). These data are in line
with findings showing that the HA binding motif on CD44
is the primary molecular constituent of CD44-HA interac-
tion. Removal of O-linked glycans did not significantly alter
the tensile strength of LS174T CD44v binding to HA
(Fig. 3 A). However, this treatment caused a small but signif-
icant decrease in the tensile strength of CD44s binding to HA
compared with the untreated control (Fig. 3 B). Our obser-
vations are in accord with others showing that O-linked
glycans positively regulate the binding of CHO-CD44s-
expressing cells (36). Taken together, our data suggest that
although O-linked glycans are not indispensable, they play
only an auxiliary role in CD44s-HA recognition.FIGURE 3 Role of glycosylation and sulfation of CD44 in CD44-HA
binding. (A and B) Average rupture force of (A) CD44v-HA and (B)
CD44s-HA as a function of contact duration. CD44v was immunoprecipi-
tated from LS174T cells cultured in medium containing either 2 mM
benzyl-GalNAc to inhibit O-linked glycosylation or DPBS. CD44s was
immunoprecipitated from HL60 cells containing either 2 mM benzyl-
GalNAc or DPBS. CD44v and CD44s were treated with PNGaseF accord-
ing to the manufacturer’s instructions to cleave N-linked glycans. (C and D)
Average rupture force of (C) CD44v-HA and (D) CD44s-HA bonds
as a function of contact duration. CD44v was immunoprecipitated from
LS174T cells cultured in medium containing either sodium chlorate
(60 mM) to block sulfation or DPBS. CD44s was immunoprecipitated
from HL60 cells cultured in medium containing either sodium chlorate
(20 mM) or DPBS. Data represent the mean 5 SE of n ¼ 3 independent
experiments performed at a retraction velocity of 20 mm/s; *p < 0.05
with respect to untreated control.Previous investigators showed a positive correlation
between N-linked glycans and CD44-HA binding in human
lymphoma, melanoma cells, lung-epithelium-derived tumor
cells expressing CD44s, and pancreatic cancer cells express-
ing CD44v (37–39). However, others reported either a
negative correlation between N-glycosylation and CD44s-
mediated HA binding on B-cells and monocytes (40,41)
or no role for N-glycans in HA binding of CD44v-express-
ing colon carcinoma cells (33). In our work, enzymatic
removal of N-linked oligosaccharides from the CD44 core
protein did not affect the frequency of binding to HA,
consistent with the notion that the HA-binding motif on
CD44 is the primary molecular constituent of CD44-HA
interaction. However, this intervention resulted in a signifi-
cant reduction in the tensile strength of HL60 CD44s-HA
binding at all contact times tested (Fig. 3 B). Interestingly,
removal of N-linked glycans reduced the average rupture
force of LS174T CD44v binding to HA only at the shorter
(and not at the longer) contact duration (Fig. 3 A). Collec-
tively, our results indicate that N-linked glycans contribute
moderately to the tensile strength of CD44-HA binding
during short (2 ms) dwell times that represent physio-
logically relevant flow conditions (0.5 dyn/cm2). At longer
dwell times (200 ms), there may be a compensatory mech-
anism to restore binding strength in the absence of N-linked
glycans on CD44v.
We next investigated the potential role of sulfation in
LS174T CD44v-HA and HL60 CD44s-HA binding. Block-
ing sulfation decreased the tensile strength of LS174T
CD44v-HA and HL60 CD44s-HA binding compared with
the untreated control at the shorter contact time, but not
during long contact durations (Fig. 3, C and D). Similar
results were previously obtained in studies of CD44s
expressing peripheral blood monocytes, SR91 human leuke-
mic cells, and L cell fibroblasts, indicating a positive corre-
lation between sulfation and CD44-HA binding (42–44).
Thus, our data suggest that sulfation contributes to the
tensile strength of CD44-HA binding during short interac-
tion times that represent physiologically relevant flow con-
ditions. Given a sufficient encounter time between CD44
and HA, such as would occur under near-static conditions,
there may be a compensatory mechanism to restore binding
strength in the absence of CD44 sulfation. This may explain
why the tensile strength was not significantly lower com-
pared with that of the untreated control at the longer
contact duration of 200 ms. These results further emphasize
the predominant role played by the binding motif on the
CD44 protein core (amino acid residues 32–123 in the
N-terminal region) in mediating the strong binding with HA.Kinetic and micromechanical properties of
CD44s-fibrin versus CD44s-fibrinogen binding
We recently reported that CD44 is the major functional
fibrin receptor on colon carcinoma cells (16,17). CD44s isBiophysical Journal 103(3) 415–423
420 Raman et al.also capable of binding immobilized fibrin(ogen) (16). We
thus wished to characterize the biophysics and molecular
requirements of CD44s binding to fibrin(ogen). Force spec-
troscopy measurements reveal that the CD44s-fibrin bond
displayed a significantly higher tensile strength than the
CD44s-fibrinogen bond for loading rates > 100 pN/s
(Fig. 4 A). Moreover, the unstressed dissociation rate was
significantly lower for CD44s-fibrin (0.44 5 0.05 s1)
than for the CD44s-fibrinogen bond (0.62 5 0.06 s1),
whereas modest differences were noted for the reactive
compliance (Table 1). We validated the Bell model parame-
ters by performing Monte Carlo simulations of bond rupture
under constant loading rates (Fig. 4 B) (13,14). Of note,
control experiments eliminated the possibility of CD44s-
thrombin interactions in our force spectroscopy measure-
ments (Fig. S2). Taken together, results indicate that the
CD44s-fibrin bond is mechanically stronger than the CD44s-
fibrinogen bond. These findings may explain the higher
capability of CD44s-fibrin compared with CD44s-fibrinogen
to mediate binding more efficiently at 0.5 dyn/cm2 (16). Of
note, the CD44s-fibrin(ogen) bonds are weaker than the
CD44-HA pairs. Furthermore, CD44s-fibrin(ogen) bonds
display a higher koff (s
1) (Table 1) and a lower overall
tensile strength in comparisonwith CD44v-P-selectin, which
is in line with the ability of selectin-ligand interactions to
mediate binding at higher hydrodynamic forces (15,19,20).
Blocking the HA-binding site on LS174T CD44v with
Hermes-1 resulted in the abrogation of LS174T CD44v-
fibrin binding compared with control (15). This finding
suggests that the HA-binding motif on LS174T CD44v is
critical for molecular recognition with fibrin, which is in
agreement with macroscopic flow-based adhesion assays
(16). Therefore, we sought to determine the effect of the
presence of Hermes-1 mAb on CD44s-fibrin and CD44s-
fibrinogen binding. Interestingly, no inhibitory effect wasFIGURE 4 Kinetic and micromechanical properties of CD44s-fibrin and
CD44s-fibrinogen interactions at the single-molecule level. (A) Rupture
force (pN) as a function of loading rate (pN/s) for CD44s-fibrin and
CD44s-fibrinogen interactions. Data were acquired for a range of retraction
velocities from 5 to 25 mm/s and using a dwell time of 20 ms. Data represent
mean 5 SE of n ¼ 4–6 experiments, where each experiment had at least
1200 approach/reproach cycles. (B) Distribution of adhesion forces ob-
tained experimentally (bars) or computed using a Monte Carlo simulation
(line) based on Bell model kinetic parameters for CD44s-fibrin interactions.
The retraction velocity was maintained for 20 mm/s.
Biophysical Journal 103(3) 415–423detected in the frequency of binding of CD44s to fibrin in
the presence of Hermes-1 relative to the untreated control
(Fig. 5 A), even though this antibody blockade caused
a small reduction in the tensile strength of this receptor-
ligand pair (Fig. 5 B). This finding suggests that the HA-
binding site on CD44s makes a minor contribution to the
recognition of fibrin, which is in stark contrast to its critical
role in LS174T CD44v-fibrin binding (15,16). Surprisingly,
this antibody treatment resulted in higher CD44s-fibrinogen
rupture forces, especially at long dwell times (Fig. 5 D).
These observations suggest that the HA-binding site modu-
lates CD44s-fibrinogen binding, and that other molecular
constituents on CD44s may be involved in the molecular
recognition of fibrinogen. These constituents may remain
cryptic during shorter contact durations. With an increase
in the encounter time, they would be able to mediate more
stable and stronger binding between CD44s and fibrinogen
(Fig. 5 D). This finding may help explain the selective inter-
action between CD44s (but not CD44v) and immobilized
fibrinogen (15,16). We speculate that the insertion of variant
exons in the CD44 stem region might disrupt the three-
dimensional structure of the fibrinogen-binding pocket on
LS174T CD44 (16). Of note, increasing the dwell time
from 2 to 200 ms did not affect the frequency of bindingFIGURE 5 Effect of Hermes-1 on CD44s-fibrin(ogen) binding. (A and B)
The frequency of binding events (A) and average rupture force (B) of CD44s
binding to fibrin were evaluated in the absence and presence of the function-
blocking CD44 antibody Hermes-1. (C and D) The frequency of binding
events (C) and average rupture force (D) of CD44s binding to fibrinogen
were evaluated in the absence and presence of Hermes-1. DMPC-CD44s
lipid solutions were premixed with 20 mg/ml of the Hermes-1 mAb just
before bilayers were formed on PEI-coated glass slides. Data represent
the mean5 SE of n ¼ 3 independent experiments; *p < 0.05 with respect
to untreated control, and **p < 0.05 with respect to CD44s binding to
fibrinogen in the presence of Hermes-1 at 2 ms.
CD44-HA and CD44-Fibrin(ogen) Binding 421events or the percentage of single or multiple CD44-
ligand bonds as estimated by Poisson distribution statistics
(Fig. S3, A and B) (15).Roles of CS and DS in CD44-fibrin(ogen) binding
Treatment of immunopurified CD44s with chondroitinase
ABC, which degrades all forms of CS and DS (2), essen-
tially abolished the frequency of binding events between
CD44s and fibrin(ogen) at both of the contact durations
tested (Fig. 6, A and B). This finding reveals crucial roles
of CS and/or DS in CD44s-fibrin(ogen) molecular recogni-
tion akin to their role in mediating LS174T CD44v-fibrin
binding (15,16). Inhibition of O-glycosylation did not alter
the frequency of CD44s-fibrin binding (Fig. S4 B), whereas
treatment of immunopurified CD44s with PNGaseF nearly
abrogated the binding to fibrin(ogen) to background levels,
suggesting that the N-linked glycans displayed on CD44s
are also responsible for its ability to bind to fibrin(ogen)
(Fig. 6, A and B). In stark contrast, O-linked (but not
N-linked) glycans play an important role in LS174T
CD44v-fibrin binding (Fig. S4 A).
Although there was no significant alteration in the
frequency of binding upon blocking sulfation on CD44s,FIGURE 6 Role of glycosylation and sulfation of CD44 in CD44-
fibrin(ogen) binding. (A and B) Frequency of binding between CD44s
treated with chondroitinase ABC (1 U/ml) or PNGaseF according to the
manufacturer’s instructions, and (A) fibrin or (B) fibrinogen as a function
of contact duration compared with untreated control. (C and D) Average
rupture force of (C) CD44s-fibrin and (D) CD44s-fibrinogen bonds as a
function of contact duration. CD44s was immunoprecipitated from HL60
cells cultured in medium containing sodium chlorate (20 mM) to block sul-
fation or DPBS. Data represent the mean5 SE of n¼ 3 independent exper-
iments performed at a retraction velocity of 20 mm/s; *p< 0.05 with respect
to untreated control.this intervention decreased the tensile strength of CD44s-
fibrinogen binding significantly at both dwell times
(Fig. 6 D). This intervention reduced the rupture force of
CD44s-fibrin binding at 2 ms (Fig. 6 C) but not at 200 ms.
This observation at the longer dwell time highlights the
difference in the binding of CD44s to fibrin versus
fibrinogen. Moreover, the effect of blocking sulfation on
CD44s-fibrin(ogen) binding is in distinct contrast to the
marked increase in the tensile strength that is observed for
CD44v-fibrin binding when sulfation is inhibited on
LS174T CD44v (15,16). Thus, it is possible that the nega-
tively charged sulfate groups on CD44s, particularly on the
stretches of CS and/or DS GAGs, facilitate the binding to
positively charged regions of the fibrin(ogen) molecule
during short interaction times. On the other hand, when the
negatively charged sulfate groups are removed from CD44v,
the stretches of unsulfated CS and/or DS GAGs may bind
to negatively charged regions of the fibrin molecule to facil-
itate strong binding even at short contact durations (15).
Our studies further emphasize the role played by GAGs in
primarily mediating the binding to fibrin(ogen), which
suggests that the HA-binding motif on the CD44s molecule
plays a modest role in fibrin(ogen) recognition. This
phenomenon is in contrast to CD44-HA binding, wherein
the HA-binding motif plays the greater role in mediating
molecular recognition when compared with the glycans.
The CD44s-binding site on fibrin is localized in the
(b15–66) regions forming fibrin bN-domains (16). Although
CD44s-coated microspheres interact efficiently with the
(Bb1–66)2 fragment, which mimics fibrinogen, at a low
shear stress level of 0.25 dyn/cm2, no binding was detected
between soluble fibrinogen and immobilized CD44s in pre-
vious surface plasmon resonance assays (16). Fibrinogen
immobilization could result in the exposure of a cryptic
binding site that is capable of mediating binding to CD44s
but not CD44v (16). In addition, removal of the fibrinopep-
tide B by thrombin during conversion of fibrinogen to fibrin
could make the binding site more accessible to CD44s. This
could also help explain the differences in kinetic and micro-
mechanical properties observed between CD44s-fibrin and
CD44s-fibrinogen binding.CONCLUDING REMARKS
In summary, we have characterized the kinetic and micro-
mechanical properties of CD44–counter-receptor interac-
tions at the single-molecule level using a combination of
force spectroscopy, which has the benefit of being highly
quantitative, and biochemical tools such as enzymatic treat-
ments and metabolic inhibitors to eliminate the potential
contribution of subtle differences of expression levels. Our
study may help reconcile the differences documented in
the literature regarding CD44 binding to HA. Also, our find-
ings provide insight into the nanomechanical functions of
CD44 with HA and fibrin(ogen), which play key roles inBiophysical Journal 103(3) 415–423
422 Raman et al.important (patho)physiological processes such as inflamma-
tion and cancer metastasis.SUPPORTING MATERIAL
Four figures are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(12)00728-X.
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